非小细胞肺癌的免疫治疗策略及研究进展  

Strategies and advances in immunotherapy of non-small cell lung cancer

作　　者：卢畅[1] 王阿曼[2] 李颖[2] 宁振[3] 刘基巍[2] 

机构地区：[1]大连医科大学研究生院,116044 [2]大连医科大学附属第一医院肿瘤科,辽宁大连116011 [3]大连医科大学附属第一医院肝胆外科,116011

出　　处：《临床肿瘤学杂志》2016年第5期452-457,共6页Chinese Clinical Oncology

基　　金：国家自然科学基金面上项目(81572881)

摘　　要：非小细胞肺癌(NSCLC)是一种高发病率和死亡率的恶性肿瘤。近年来以手术、放疗、化疗和靶向治疗为主的综合治疗均取得了一定进展,但晚期NSCLC患者的远期生存率仍然较低。免疫治疗主要通过特异性地增强机体的抗肿瘤免疫应答来杀伤肿瘤细胞。以免疫检查点抑制剂、抗原特异性肿瘤疫苗等为代表的多种新型免疫治疗药物在近期临床试验中显示出较好的疗效,从而使得NSCLC的治疗取得突破性进展。免疫治疗将成为NSCLC重要的治疗新模式。Non-small cell lung cancer（NSCLC） is a highly prevalent and aggressive disease. In recent years, the long time survival rate of patients with advanced NSCLC remains low despite of advances in surgery, irradiation, chemotherapy and targeted ther-apy. The aim of immunotherapy is to specifically enhance the immune response directed to the tumor. Many trials have addressed the role of novel immunotherapeutic agents, such as checkpoint inhibitors and antigenspecific tumour vaccines, which has made break-through progress in NSCLC. Immunotherapy will be a fundamentally new concept for the treatment of NSCLC.

关 键 词：免疫治疗 非小细胞肺癌 免疫检查点抑制剂 肿瘤疫苗 

分 类 号：R734.2[医药卫生—肿瘤]